Ultragenyx Pharmaceutical, Inc.

FGIM primarily provides advice with respect to equity investment strategies; however, they do not recommend a particular type of security. The firm is a multi strategy investor that manages portfolios of equity and fixed-income investments for institutional and private clients. Their strategies include core international/emerging market equities; international equity; international small- and mid-cap equity; balanced/asset allocation; managed risk and the Kaufmann Accounts. The Kauffman strategy invests in small, mid or large cap stocks, utilizing a fundamental bottom-up process seeking growth companies and may invest in less developed or emerging markets.

Alkeon Capital Management invests principally, but not solely, in long or short positions of publicly-traded and private companies in global markets on behalf of the funds it manages. They provides advisory or sub-advisory services to its clients using the general strategy except that (a) the Alkeon Growth Funds, the OAM Funds, ALPRO Growth, MS UCITs and the Insurance Series primarily invest in long and short positions of global growth stocks; (b) the Alkeon Select Funds and the Alkeon Capital Partners Fund invest primarily in long positions of global growth stocks; and (c) the Alkeon Asia Growth Funds invest primarily in long and short positions of global growth stocks based in the Asia Pacific region. Alkeon Capital Management employs a bottom-up, fundamentally driven, research-intensive approach to investing. On the long side, their investment program focuses on investing in the equity securities of companies that Alkeon believes are well positioned to benefit from demand for their products or services, including companies that can innovate or grow rapidly relative to their peers in their markets. On the short side, Alkeon Capital Management may affect short sales of securities when it believes that the market price of a security is above its estimated intrinsic or fundamental value. This analytical process involves the use of valuation models, review and analysis of published research, and, in some cases, discussions with industry experts and company visits. Alkeon also takes into account economic and market conditions.

RSCM applies a research-intensive, fundamental approach to investing the funds across multiple healthcare subsectors, with a focus on allocating capital to the highest conviction ideas. The firm's investment process leverages a long-term horizon, seeking to take advantage of the healthcare sector's inherent volatility to increase position sizes over time. The funds RSCM provides investment advisory services to are permitted to make a limited amount of investments in private companies and may make investments in companies outside of healthcare-related industries, as the firm determines to be appropriate for the funds' overall portfolio balance and long-term investment strategy.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

TPG Biotech is a life science venture capital platform of TPG Capital. TPG Biotech focuses on therapeutics, medical devices, and healthcare services. By leveraging TPG''s global network to support portfolio companies, TPG Biotech provides access to opportunities and operational experts from other platforms. They target investments globally with a particular focus on opportunities in North America & Asia Pacific, and provides financing for early & later stage capital requirements.

Impresa focuses on early-stage investments in start-up companies across US and International portfolio companies. There fund focuses on companies operating in the fields of biopharmaceutical, medical technology & healthcare IT and services.There funds are larger and more global. In the US and Europe, they are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, there sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai with over $2 trillion in assets under management.